Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1
Cancer Gene Therapy,  Clinical Article

Ou W et al. – This study suggests that the combination of LKB1 gene therapy with low–dose cisplatin–based chemotherapy may be a potent therapeutic strategy for lung cancer.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer Journal of Clinical Oncology, November 19, 2014    Clinical Article

2 Serum vitamin D, vitamin D binding protein, and lung cancer survival Lung Cancer, November 14, 2014    Clinical Article

3 Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with non-adenocarcinoma non-small cell lung cancer Annals of Oncology, November 20, 2014    Clinical Article

4 Detection of lung cancer through low-dose CT screening (NELSON): A prespecified analysis of screening test performance and interval cancers The Lancet Oncology, November 4, 2014    Clinical Article

5 Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data The Lancet Oncology, September 24, 2014    Clinical Article

6 Clinical next-generation sequencing in patients with non–small cell lung cancer Cancer, November 14, 2014    Clinical Article

7 Systematic mediastinal lymphadenectomy or mediastinal lymph node sampling in patients with pathological stage I NSCLC: A meta-analysis World Journal of Surgery, October 13, 2014    Evidence Based Medicine

8 Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial The Lancet Oncology, November 5, 2014    Clinical Article

9 Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know Anticancer Research, October 27, 2014    Review Article

10 Lung squamous cell carcinomas with basaloid histology represent a specific molecular entity Clinical Cancer Research, November 11, 2014    Clinical Article

11 Pemetrexed versus gefitinib as a second-line treatment in advanced non-squamous non-small-cell lung cancer patients harbouring wild-type EGFR (CTONG0806): A multicenter randomized trial Annals of Oncology, October 14, 2014    Clinical Article

12 Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial The Lancet Oncology, November 10, 2014    Clinical Article

13 Identification of independent primary tumors and intrapulmonary metastases using DNA rearrangements in non-small-cell lung cancer Journal of Clinical Oncology, November 17, 2014    Clinical Article

14 Prophylactic cranial irradiation for patients with small-cell lung cancer: A systematic review of the literature with meta-analysis Full Text BMC Cancer, November 21, 2014    Free full text    Evidence Based Medicine    Review Article

15 Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non–small-cell lung cancer Journal of Clinical Oncology, November 3, 2014    Clinical Article

16 An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells Journal of Leukocyte Biology, November 4, 2014    Clinical Article

17 The impact of diagnostic imaging wait times on the prognosis of lung cancer Canadian Association of Radiologists Journal , November 10, 2014    Clinical Article

18 Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial The Lancet Oncology, October 22, 2014    Clinical Article

19 Prognostic impact of COX-2 in non-small cell lung cancer: A comprehensive compartment-specific evaluation of tumor and stromal cell expression Cancer Letters, November 24, 2014    Clinical Article

20 Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway Anti-Cancer Drugs, October 22, 2014    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore